Thomas Damgaard Sandahl

The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease. / Glavind, Emilie; Gotthardt, Daniel N.; Pfeiffenberger, Jan; Sandahl, Thomas Damgaard; Bashlekova, Teodora; Willemoe, Gro Linno; Hasselby, Jane Preuss; Weiss, Karl Heinz; Møller, Holger Jon; Vilstrup, Hendrik; Lee, William M.; Schilsky, Michael L.; Ott, Peter; Grønbæk, Henning.

In: Orphanet Journal of Rare Diseases, Vol. 15, 173, 07.2020.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Glavind, E, Gotthardt, DN, Pfeiffenberger, J, Sandahl, TD, Bashlekova, T, Willemoe, GL, Hasselby, JP, Weiss, KH, Møller, HJ, Vilstrup, H, Lee, WM, Schilsky, ML, Ott, P & Grønbæk, H 2020, 'The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease', Orphanet Journal of Rare Diseases, vol. 15, 173. https://doi.org/10.1186/s13023-020-01452-2

APA

Glavind, E., Gotthardt, D. N., Pfeiffenberger, J., Sandahl, T. D., Bashlekova, T., Willemoe, G. L., Hasselby, J. P., Weiss, K. H., Møller, H. J., Vilstrup, H., Lee, W. M., Schilsky, M. L., Ott, P., & Grønbæk, H. (2020). The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease. Orphanet Journal of Rare Diseases, 15, [173]. https://doi.org/10.1186/s13023-020-01452-2

CBE

Glavind E, Gotthardt DN, Pfeiffenberger J, Sandahl TD, Bashlekova T, Willemoe GL, Hasselby JP, Weiss KH, Møller HJ, Vilstrup H, Lee WM, Schilsky ML, Ott P, Grønbæk H. 2020. The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease. Orphanet Journal of Rare Diseases. 15:Article 173. https://doi.org/10.1186/s13023-020-01452-2

MLA

Vancouver

Author

Glavind, Emilie ; Gotthardt, Daniel N. ; Pfeiffenberger, Jan ; Sandahl, Thomas Damgaard ; Bashlekova, Teodora ; Willemoe, Gro Linno ; Hasselby, Jane Preuss ; Weiss, Karl Heinz ; Møller, Holger Jon ; Vilstrup, Hendrik ; Lee, William M. ; Schilsky, Michael L. ; Ott, Peter ; Grønbæk, Henning. / The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease. In: Orphanet Journal of Rare Diseases. 2020 ; Vol. 15.

Bibtex

@article{fa54f93bf0814eb8b0396c3411f9778f,
title = "The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease",
abstract = "BACKGROUND: Macrophages play a significant role in liver disease development and progression. The macrophage activation marker soluble (s)CD163 is associated with severity and prognosis in a number of different acute and chronic liver diseases but has been only sparsely examined in Wilson's disease (WD). We investigated sCD163 levels in patients with acute and chronic WD and hypothesized associations with liver disease phenotype and biochemical markers of liver injury. METHODS: We investigated sCD163 in two independent cohorts of WD patients: 28 patients with fulminant WD from the US Acute Liver Failure (ALF) Study Group registry and 147 patients with chronic disease from a German WD registry. We included a control group of 19 healthy individuals. Serum sCD163 levels were measured by ELISA. Liver CD163 expression was determined by immunohistochemistry. RESULTS: In the ALF cohort, median sCD163 was 10-fold higher than in healthy controls (14.6(2.5-30.9) vs. 1.5(1.0-2.7) mg/L, p < 0.001). In the chronic cohort, median sCD163 was 2.6(0.9-24.9) mg/L. There was no difference in sCD163 according to subgroups based on initial clinical presentation, i.e. asymptomatic, neurologic, hepatic, or mixed. Patients with cirrhosis at the time of diagnosis had higher sCD163 compared with those without cirrhosis (3.0(1.2-24.9) vs. 2.3(0.9-8.0) mg/L, p < 0.001); and both cohorts significantly lower than the ALF patients. Further, sCD163 correlated positively with ALT, AST, GGT and INR (rho = 0.27-0.53); and negatively with albumin (rho = - 0.37), (p ≤ 0.001, all). We observed immunohistochemical CD163 expression in liver tissue from ALF patients. CONCLUSIONS: Although sCD163 is not specific for WD, it was elevated in WD patients, especially in those with ALF. Further, sCD163 was higher in patients with cirrhosis compared to patients without cirrhosis and associated with biochemical markers of liver injury and hepatocellular function. Thus, macrophage activation is evident in WD and associates with liver disease phenotype and biochemical parameters of liver disease. Our findings suggest that sCD163 may be used as a marker of liver disease severity in WD patients.",
keywords = "Acute liver failure, Biomarker, Liver cirrhosis, Macrophage activation, Wilson{\textquoteright}s disease",
author = "Emilie Glavind and Gotthardt, {Daniel N.} and Jan Pfeiffenberger and Sandahl, {Thomas Damgaard} and Teodora Bashlekova and Willemoe, {Gro Linno} and Hasselby, {Jane Preuss} and Weiss, {Karl Heinz} and M{\o}ller, {Holger Jon} and Hendrik Vilstrup and Lee, {William M.} and Schilsky, {Michael L.} and Peter Ott and Henning Gr{\o}nb{\ae}k",
year = "2020",
month = jul,
doi = "10.1186/s13023-020-01452-2",
language = "English",
volume = "15",
journal = "Orphanet Journal of Rare Diseases",
issn = "1750-1172",
publisher = "BioMed Central",

}

RIS

TY - JOUR

T1 - The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease

AU - Glavind, Emilie

AU - Gotthardt, Daniel N.

AU - Pfeiffenberger, Jan

AU - Sandahl, Thomas Damgaard

AU - Bashlekova, Teodora

AU - Willemoe, Gro Linno

AU - Hasselby, Jane Preuss

AU - Weiss, Karl Heinz

AU - Møller, Holger Jon

AU - Vilstrup, Hendrik

AU - Lee, William M.

AU - Schilsky, Michael L.

AU - Ott, Peter

AU - Grønbæk, Henning

PY - 2020/7

Y1 - 2020/7

N2 - BACKGROUND: Macrophages play a significant role in liver disease development and progression. The macrophage activation marker soluble (s)CD163 is associated with severity and prognosis in a number of different acute and chronic liver diseases but has been only sparsely examined in Wilson's disease (WD). We investigated sCD163 levels in patients with acute and chronic WD and hypothesized associations with liver disease phenotype and biochemical markers of liver injury. METHODS: We investigated sCD163 in two independent cohorts of WD patients: 28 patients with fulminant WD from the US Acute Liver Failure (ALF) Study Group registry and 147 patients with chronic disease from a German WD registry. We included a control group of 19 healthy individuals. Serum sCD163 levels were measured by ELISA. Liver CD163 expression was determined by immunohistochemistry. RESULTS: In the ALF cohort, median sCD163 was 10-fold higher than in healthy controls (14.6(2.5-30.9) vs. 1.5(1.0-2.7) mg/L, p < 0.001). In the chronic cohort, median sCD163 was 2.6(0.9-24.9) mg/L. There was no difference in sCD163 according to subgroups based on initial clinical presentation, i.e. asymptomatic, neurologic, hepatic, or mixed. Patients with cirrhosis at the time of diagnosis had higher sCD163 compared with those without cirrhosis (3.0(1.2-24.9) vs. 2.3(0.9-8.0) mg/L, p < 0.001); and both cohorts significantly lower than the ALF patients. Further, sCD163 correlated positively with ALT, AST, GGT and INR (rho = 0.27-0.53); and negatively with albumin (rho = - 0.37), (p ≤ 0.001, all). We observed immunohistochemical CD163 expression in liver tissue from ALF patients. CONCLUSIONS: Although sCD163 is not specific for WD, it was elevated in WD patients, especially in those with ALF. Further, sCD163 was higher in patients with cirrhosis compared to patients without cirrhosis and associated with biochemical markers of liver injury and hepatocellular function. Thus, macrophage activation is evident in WD and associates with liver disease phenotype and biochemical parameters of liver disease. Our findings suggest that sCD163 may be used as a marker of liver disease severity in WD patients.

AB - BACKGROUND: Macrophages play a significant role in liver disease development and progression. The macrophage activation marker soluble (s)CD163 is associated with severity and prognosis in a number of different acute and chronic liver diseases but has been only sparsely examined in Wilson's disease (WD). We investigated sCD163 levels in patients with acute and chronic WD and hypothesized associations with liver disease phenotype and biochemical markers of liver injury. METHODS: We investigated sCD163 in two independent cohorts of WD patients: 28 patients with fulminant WD from the US Acute Liver Failure (ALF) Study Group registry and 147 patients with chronic disease from a German WD registry. We included a control group of 19 healthy individuals. Serum sCD163 levels were measured by ELISA. Liver CD163 expression was determined by immunohistochemistry. RESULTS: In the ALF cohort, median sCD163 was 10-fold higher than in healthy controls (14.6(2.5-30.9) vs. 1.5(1.0-2.7) mg/L, p < 0.001). In the chronic cohort, median sCD163 was 2.6(0.9-24.9) mg/L. There was no difference in sCD163 according to subgroups based on initial clinical presentation, i.e. asymptomatic, neurologic, hepatic, or mixed. Patients with cirrhosis at the time of diagnosis had higher sCD163 compared with those without cirrhosis (3.0(1.2-24.9) vs. 2.3(0.9-8.0) mg/L, p < 0.001); and both cohorts significantly lower than the ALF patients. Further, sCD163 correlated positively with ALT, AST, GGT and INR (rho = 0.27-0.53); and negatively with albumin (rho = - 0.37), (p ≤ 0.001, all). We observed immunohistochemical CD163 expression in liver tissue from ALF patients. CONCLUSIONS: Although sCD163 is not specific for WD, it was elevated in WD patients, especially in those with ALF. Further, sCD163 was higher in patients with cirrhosis compared to patients without cirrhosis and associated with biochemical markers of liver injury and hepatocellular function. Thus, macrophage activation is evident in WD and associates with liver disease phenotype and biochemical parameters of liver disease. Our findings suggest that sCD163 may be used as a marker of liver disease severity in WD patients.

KW - Acute liver failure

KW - Biomarker

KW - Liver cirrhosis

KW - Macrophage activation

KW - Wilson’s disease

UR - http://www.scopus.com/inward/record.url?scp=85087471778&partnerID=8YFLogxK

U2 - 10.1186/s13023-020-01452-2

DO - 10.1186/s13023-020-01452-2

M3 - Journal article

C2 - 32615997

AN - SCOPUS:85087471778

VL - 15

JO - Orphanet Journal of Rare Diseases

JF - Orphanet Journal of Rare Diseases

SN - 1750-1172

M1 - 173

ER -